OPTN
OptiNose, Inc. NASDAQ$9.60
Mkt Cap $97.2M
52w Low $4.82
31.5% of range
52w High $20.02
50d MA $8.91
200d MA $8.83
P/E (TTM)
-3.1x
EV/EBITDA
-93.8x
P/B
-1.7x
Debt/Equity
-3.2x
ROE
-485.6%
P/FCF
-1.5x
RSI (14)
—
ATR (14)
—
Beta
-0.89
50d MA
$8.91
200d MA
$8.83
Avg Volume
117.7K
About
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusiti…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2025 | AMC | -0.74 | -1.01 | -36.5% | 9.42 | +0.0% | +1.1% | +2.9% | +3.1% | +1.9% | +1.9% | — |
| Mar 26, 2025 | AMC | -0.70 | -0.03 | +95.7% | 9.17 | +0.2% | -0.3% | -0.2% | +0.0% | -0.2% | -0.1% | — |
| Nov 12, 2024 | AMC | -0.05 | 0.00 | +105.4% | 9.00 | -1.7% | -15.4% | -24.1% | -27.4% | -35.8% | -43.6% | — |
| Aug 8, 2024 | AMC | -1.20 | -1.05 | +12.5% | 14.25 | -2.1% | -6.3% | -4.1% | +0.5% | -3.7% | -3.2% | — |
| May 14, 2024 | AMC | -1.50 | -1.80 | -20.0% | 16.95 | -0.9% | +4.8% | +14.2% | +11.5% | +6.2% | +2.7% | — |
| Mar 7, 2024 | AMC | -1.50 | -1.35 | +10.0% | 25.80 | +0.0% | -2.3% | +8.1% | +10.2% | +12.2% | +10.5% | — |
| Nov 9, 2023 | AMC | -1.50 | -1.20 | +20.0% | 18.30 | -1.6% | +0.8% | +0.0% | +2.5% | +1.6% | +2.5% | — |
| Aug 10, 2023 | AMC | -1.65 | 0.30 | +118.2% | 18.60 | -2.4% | +0.8% | +0.0% | +0.0% | +1.2% | +0.8% | — |
| May 11, 2023 | AMC | -2.40 | -2.55 | -6.2% | 29.70 | -1.5% | -1.5% | -1.5% | -5.1% | -6.3% | -9.6% | — |
| Mar 7, 2023 | AMC | -2.40 | -2.55 | -6.2% | 27.90 | +2.2% | +2.2% | -6.5% | -8.1% | -5.9% | -3.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.69 | $9.62 | -0.7% | +0.2% | -0.9% | -0.9% | — | — |
| Mar 21 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $9.15 | $9.12 | -0.3% | +0.0% | +0.2% | +0.2% | +0.2% | -0.1% |
| Mar 21 | Piper Sandler | Downgrade | Overweight → Neutral | — | $9.15 | $9.12 | -0.3% | +0.0% | +0.2% | +0.2% | +0.2% | -0.1% |
| Mar 20 | Lake Street | Downgrade | Buy → Hold | — | $6.00 | $9.50 | +58.3% | +52.5% | +52.5% | +52.8% | +52.8% | +52.8% |
| Jan 16 | Lake Street | Maintains | Buy → Buy | — | $6.00 | $6.07 | +1.2% | +0.5% | +6.3% | +15.3% | +11.5% | +9.3% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.70 | $6.81 | +1.6% | -3.0% | -8.7% | -11.0% | -15.5% | -20.9% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.00 | $8.85 | -1.7% | -15.4% | -24.1% | -27.4% | -35.8% | -43.6% |
| Nov 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.00 | $8.85 | -1.7% | -15.4% | -24.1% | -27.4% | -35.8% | -43.6% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.95 | $16.80 | -0.9% | +4.8% | +14.2% | +11.5% | +6.2% | +2.7% |
| May 15 | Lake Street | Maintains | Buy → Buy | — | $16.95 | $16.80 | -0.9% | +4.8% | +14.2% | +11.5% | +6.2% | +2.7% |
Data updated apr 30, 2026 4:48pm
· Source: massive.com